Category: Uncategorized

Frontline Niraparib, Bevacizumab Shows Activity In Certain Patients With Advanced Ovarian Cancer

Targeted Oncology  (4/13, Columbus) reports, “Frontline niraparib (Zejula) in addition to bevacizumab (Avastin) as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response (PR) to frontline platinum-based chemotherapy with bevacizumab,” phase 2 data show. Findings were issued for the virtual SGO 2020 Annual Meeting. […]

Read More

Trastuzumab Addition Improves Survival In HER2-Positive Uterine Serous Carcinoma

 (4/10, Rosa) reported, “The addition of trastuzumab (Herceptin) to carboplatin and paclitaxel resulted in a significant survival benefit in women with advanced or recurrent, HER2-positive uterine serous carcinoma, with the greatest benefit observed in those with stage III/IV disease who received the regimen up front,” updated phase 2 data demonstrate. In addition, the regimen “led […]

Read More

BRCA Testing Rates Have Increased In Ovarian Cancer, Although Researchers Find The Rates To Still Be Suboptimal

Cancer Therapy Advisor (4/1, Moench) reports that “results of a retrospective analysis of real-world clinical data from patients with ovarian cancer showed a temporal trend for increased rates of BRCA testing in the setting of ovarian cancer, although BRCA testing rates remained suboptimal,” according to findings that “were submitted to the Society of Gynecologic Oncology (SGO) […]

Read More

African-American Women Are More Likely To Have Uterine Cancer Characterized As Serous Carcinoma As Well As A Higher Frequency Of TP53-Mutated Endothelial Carcinoma Compared With White Women

Cancer Therapy Advisor (3/31, Moench) reports that “results of a tumor profiling study of uterine cancer specimens revealed that African-American women were significantly more likely to have uterine cancer characterized as serous carcinoma as well as a higher frequency of TP53-mutated endothelial carcinoma compared with white women.” The “findings were submitted to the Society of Gynecologic […]

Read More

Women With Early-Stage SCC Of Vulva, With Negative SLN At Time Of Surgery, May Have Low Risk Of Recurrent Disease In Groin, Study Suggests

Cancer Therapy Advisor (3/30, Moench) reports “results of a large prospective observational study that followed women with early-stage squamous cell carcinoma (SCC) of the vulva characterized by a negative sentinel lymph node biopsy (SLN) at the time of surgery showed these patients to have a low risk of recurrent disease in the groin.” In the study, […]

Read More